Last reviewed · How we verify
Brimonidine Tartrate 0.01%
Brimonidine Tartrate 0.01% is a Small molecule drug developed by Eye Therapies, LLC. It is currently in Phase 2 development.
At a glance
| Generic name | Brimonidine Tartrate 0.01% |
|---|---|
| Sponsor | Eye Therapies, LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA) (PHASE4)
- Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG) (PHASE4)
- Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves (PHASE4)
- A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension (PHASE2)
- A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension (PHASE4)
- Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension (PHASE3)
- A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Brimonidine Tartrate 0.01% CI brief — competitive landscape report
- Brimonidine Tartrate 0.01% updates RSS · CI watch RSS
- Eye Therapies, LLC portfolio CI
Frequently asked questions about Brimonidine Tartrate 0.01%
What is Brimonidine Tartrate 0.01%?
Brimonidine Tartrate 0.01% is a Small molecule drug developed by Eye Therapies, LLC.
Who makes Brimonidine Tartrate 0.01%?
Brimonidine Tartrate 0.01% is developed by Eye Therapies, LLC (see full Eye Therapies, LLC pipeline at /company/eye-therapies-llc).
What development phase is Brimonidine Tartrate 0.01% in?
Brimonidine Tartrate 0.01% is in Phase 2.
Related
- Manufacturer: Eye Therapies, LLC — full pipeline